Enanta is advancing zelicapavir to Phase III trials after CMO Dr Scott Rottinghaus said it is justified by the Phase IIb data ...

The Food and Drug Administration (FDA) has flagged a rare but potential link between the RSV vaccine—particularly Arexvy—and neurological complications. That includes Guillain-Barré syndrome, a rare ...

We’re still in the early stages of RSV season, but doctors are already worried about a rise in cases. As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in ...

Maternal immunisation against RSV is not just a scientific advancement. It is a public health imperative. By protecting ...

As the United States heads into the colder weather months, cases of respiratory syncytial virus (RSV) have been ticking up across the country. For the week ending Nov. 25, there were 8,863 positive ...

Enanta Pharmaceuticals said its experimental respiratory syncytial virus treatment significantly quickened recovery in a mid-stage study of adults at high risk of complications from the infection.

Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults.

Investors were spooked by the miss, and shares in Nasdaq-listed Enanta were down around 11%, having risen sharply in ...

RSV-related ARI was associated with a significant hospitalization burden in older adults, but its clinical severity was similar to that of influenza-related ARI.